$PCSA News

Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference

Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study

Processa Completes Enrollment And Dosing Of 20 Patients For Planned Formal Interim Analysis In Ongoing Phase 2 Clinical Study Evaluating NGC-Cap In Patients With Breast Cancer; Interim Data To Be Reported In Q1

Why Is Small-Cap Processa Pharmaceuticals Stock Rallying After Breast Cancer Trial Data?

Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer

Processa Pharmaceuticals Shares Halted On Circuit Breaker To The Upside, Stock Now Up 163.39%

Processa Pharmaceuticals Shares Halted On Circuit Breaker To The Upside, Stock Now Up 163.39%

Processa Pharmaceuticals shares are trading higher after the company reported preliminary Phase 2 data showing PCS6422 plus capecitabine increased cancer-killing metabolite exposure while maintaining comparable safety to capecitabine monotherapy.

Processa Pharmaceuticals Shares Halted On Circuit Breaker To The Upside, Stock Now Up 97.84%

Processa Pharmaceuticals Shares Resume Trade

Will Processa Pharmaceuticals (NASDAQ:PCSA) Spend Its Cash Wisely?

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Processa Pharma Provides Clinical Update On Ongoing Phase 2 Study Of NGC-Cap, Combination Treatment Of PCS6422 And Capecitabine, In Patients With Advanced Or Metastatic Breast Cancer

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Processa Pharmaceuticals To Effect 1-For-25 Reverse Stock Split

Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025

Processa Pharma's Abstract, "Adaptive Phase 2/3 Study For PCS499 (499) In Patients With Focal Segmental Glomerulosclerosis (FSGS)", Accepted For Presentation At ASN Kidney Week 2025

Processa Pharmaceuticals shares are trading higher. The stock has recently gained social media buzz.

Why Processa Pharmaceuticals Stock Rose Almost 38% Overnight?

HC Wainwright & Co. Maintains Buy on Processa Pharmaceuticals, Lowers Price Target to $1